The stock of Diplomat Pharmacy Inc (NYSE:DPLO) is a huge mover today! About 330,948 shares traded hands. Diplomat Pharmacy Inc (NYSE:DPLO) has declined 53.15% since April 22, 2016 and is downtrending. It has underperformed by 58.56% the S&P500.
The move comes after 6 months positive chart setup for the $1.01B company. It was reported on Nov, 25 by Barchart.com. We have $15.39 PT which if reached, will make NYSE:DPLO worth $30.30 million more.
Analysts await Diplomat Pharmacy Inc (NYSE:DPLO) to report earnings on March, 6. They expect $0.19 EPS, down 9.52% or $0.02 from last year’s $0.21 per share. DPLO’s profit will be $12.84M for 19.66 P/E if the $0.19 EPS becomes a reality. After $0.21 actual EPS reported by Diplomat Pharmacy Inc for the previous quarter, Wall Street now forecasts -9.52% negative EPS growth.
Diplomat Pharmacy Inc (NYSE:DPLO) Ratings Coverage
Out of 10 analysts covering Diplomat Pharmacy (NYSE:DPLO), 2 rate it a “Buy”, 1 “Sell”, while 7 “Hold”. This means 20% are positive. Diplomat Pharmacy has been the topic of 17 analyst reports since August 4, 2015 according to StockzIntelligence Inc. On Wednesday, May 11 the stock rating was maintained by Mizuho with “Neutral”. The stock of Diplomat Pharmacy Inc (NYSE:DPLO) has “Outperform” rating given on Tuesday, August 4 by Leerink Swann. The stock of Diplomat Pharmacy Inc (NYSE:DPLO) has “Neutral” rating given on Wednesday, October 14 by Bank of America. UBS initiated it with “Buy” rating and $35 target price in Wednesday, October 21 report. Barclays Capital initiated Diplomat Pharmacy Inc (NYSE:DPLO) on Wednesday, January 6 with “Overweight” rating. As per Friday, June 24, the company rating was initiated by Cowen & Co. Morgan Stanley downgraded the stock to “Equal-Weight” rating in Friday, October 2 report. The stock of Diplomat Pharmacy Inc (NYSE:DPLO) earned “Mkt Perform” rating by Avondale on Thursday, November 3. The company was maintained on Thursday, November 3 by Mizuho. As per Tuesday, June 7, the company rating was maintained by Bank of America.
According to Zacks Investment Research, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan.”
Insitutional Activity: The institutional sentiment increased to 1.82 in Q2 2016. Its up 0.39, from 1.43 in 2016Q1. The ratio increased, as 17 funds sold all Diplomat Pharmacy Inc shares owned while 46 reduced positions. 23 funds bought stakes while 67 increased positions. They now own 50.07 million shares or 2.77% more from 48.72 million shares in 2016Q1.
Jpmorgan Chase holds 0% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO) for 275,647 shares. First Tru Advsrs Lp has 24,398 shares for 0% of their US portfolio. Geode Capital Management Lc holds 0% or 253,828 shares in its portfolio. Parkside Financial Bank & holds 71 shares or 0% of its portfolio. Morgan Stanley last reported 50,663 shares in the company. Sivik Glob Healthcare Llc has invested 1.13% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO). Pinebridge Limited Partnership last reported 4,602 shares in the company. Weatherbie Cap Lc reported 259,175 shares or 1.29% of all its holdings. Louisiana State Employees Retirement last reported 0.03% of its portfolio in the stock. The Germany-based Deutsche Fincl Bank Ag has invested 0% in Diplomat Pharmacy Inc (NYSE:DPLO). Nuveen Asset Mgmt Ltd Llc holds 0.01% or 34,815 shares in its portfolio. Comml Bank Of America De, a North Carolina-based fund reported 107,707 shares. Hermes Invest reported 884,459 shares or 0.62% of all its holdings. Moreover, Creative Planning has 0% invested in Diplomat Pharmacy Inc (NYSE:DPLO) for 2,970 shares. Aberdeen Asset Public Limited Com Uk, a United Kingdom-based fund reported 66,062 shares.
Insider Transactions: Since August 1, 2016, the stock had 0 insider buys, and 2 insider sales for $1.04 million net activity. $602,358 worth of Diplomat Pharmacy Inc (NYSE:DPLO) shares were sold by Kaddis Atheer A.
More recent Diplomat Pharmacy Inc (NYSE:DPLO) news were published by: Businesswire.com which released: “DPLO LOSS ALERT: Rosen Law Firm Reminds Diplomat Pharmacy, Inc. Investors of …” on November 17, 2016. Also Fool.com published the news titled: “Why Diplomat Pharmacy, Inc. Is Plunging Today” on November 03, 2016. Prnewswire.com‘s news article titled: “Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Diplomat Pharmacy …” with publication date: November 16, 2016 was also an interesting one.
DPLO Company Profile
Diplomat Pharmacy, Inc. (Diplomat), incorporated on March 26, 1975, operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. The Firm operates through specialty pharmacy services segment. The Firm provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Firm offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company’s specialty drug dispensing services include patient care coordination, clinical services, compliance and persistency programs, patient financial assistance, specialty pharmacy training/consulting (Diplomat University), benefits investigation, prior authorization and risk evaluation and medication strategy (REMS).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.